| Revenue growth | 32.2% YoY for FY26; 21.2% for Q4 FY26. |
|---|---|
| Margins | FY26 Adjusted EBITDA margin improved to 23.8% from 22.9%. |
| Demand visibility | Strong, driven by rising global CKD prevalence and under-penetration. |
| Management confidence | High, citing scalability of operating model across global markets. |
Growth
FY26 Revenue grew 32.2% YoY to ₹998.8 Cr; Adjusted PAT surged 74.6% to ₹128.3 Cr.
Outlook
Focus on deepening India presence and scaling international businesses in Uzbekistan, Philippines, and Saudi Arabia for FY27.
Risks
High concentration of Chronic Kidney Disease risk factors (Diabetes/Hypertension); clinical replicability challenges in non-standardized specialties.
Earnings Call filed with NSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹643.00
- Market cap
- ₹6,452 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 75.8×Sector 53.1×
- Promoter holding
- 63.85%+0.00% QoQ
- FII holding
- 8.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Credit Rating
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Merger & Restructuring
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare Health Services Merger & Restructuring Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
- Value
- ₹10.25 Cr
- dialysis center acquired
- 1 dialysis centers
Nephrocare Health Services Acquisition Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
- Value
- ₹10.25 Cr
Nephrocare Health Services Employee Stock Options
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephrocare Health Services Acquisition Worth ₹11.63 Cr
Nephroplus Health Services Kazakhstan LLP will acquire a 100% stake in 'Dialysis Center Almaty' LLP for approximately ₹11.64 Crore to expand its international dialysis network.
- Value
- ₹11.63 Cr